Advert - Sanofi - CASE/0518/03/25

For an article published in a UK Sunday newspaper (that was based on an interview with a Sanofi global senior leader), which promoted Sanofi’s medicine, Beyfortus (nirsevimab), to the public, as well as making misleading claims about Beyfortus and disparaging Pfizer’s vaccine, Sanofi was ruled in breach of the following clauses of the 2024 Code:

Clause 2     - Bringing discredit upon, and reducing confidence in, the pharmaceutical industry
Clause 5.1     - Failing to maintain high standards
Clause 6.1     - Making a misleading claim
Clause 6.2     - Making an unsubstantiated claim
Clause 6.6     - Disparaging another company’s medicine
Clause 26.1     - Advertising a prescription only medicine to the public
Clause 26.2     - Providing unbalanced information and encouraging members of the public to 
ask for a specific prescription only medicine

 

Advert 2 February - Sanofi